CG Oncology's immunotherapy reduces tumor recurrence risk in bladder cancer trial
CGON•CG Oncology said its experimental immunotherapy reduced the risk of tumor recurrence by 68% in certain patients with bladder cancer, meeting the main goal of a late-stage study. The company expects to submit an FDA application before the end of March 2027.
1. Trial results
In a 367-patient trial, cretostimogene grenadenorepvec reduced the risk of tumor recurrence by 68% in patients with intermediate-risk non-muscle-invasive bladder cancer following complete tumor resection. The treatment was generally well tolerated, with safety results consistent with those reported in previous studies, the company said.
2. Next steps
CG Oncology expects to submit its application to the U.S. Food and Drug Administration before the end of March 2027, allowing it to incorporate additional data and a broader patient population. The company will present more data at a conference in December.
3. Disease context
About 75% of newly diagnosed bladder cancers are non-muscle-invasive. These cancers can return, and some tumors can grow into the bladder muscle. Cretostimogene is also being studied in patients whose disease persists or recurs despite adequate Bacillus Calmette-Guerin treatment.




